International Markets and Edwards Lifesciences (EW): A Deep Dive for Investors
Explore Edwards Lifesciences' (EW) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Lost Money on Edwards Lifesciences Corporation (EW)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
EW Shareholders Have Opportunity to Lead Edwards Lifesciences Corporation Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards" or "the Company") (NYSE:EW) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Edwards securities between February 6, 2024, and July 24, 2024, inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Edwards Lifesciences Corporation - EW
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE:EW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Investors Are Invited To Join The Schall Law Firm In A Securities Fraud Case Against Edwards Lifesciences Corporation
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024.
EW INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Edwards Lifesciences Corporation Stockholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards" or "the Company") (NYSE:EW) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Edwards securities between February 6, 2024, and July 24, 2024, inclusive (the "Class Period").
EW FRAUD NEWS: Edwards Lifesciences Sued for Securities Fraud after Stock Plummets 31%; Investors with Losses Urged to Contact BFA Law by December 13 Court Deadline
NEW YORK, NY / ACCESSWIRE / October 26, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting Click Here
Edwards Lifesciences Corporation Is Being Sued For Violating Securities Laws And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024.
EW REMINDER: Kessler Topaz Meltzer & Check, LLP Urges EW Investors with Losses to Contact the Firm
RADNOR, PA / ACCESSWIRE / October 26, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE:EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Edwards losses, you may CLICK HERE or go to: Click Here You can also contact attorney Jonathan Naji, Esq.
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
I reiterate my “Strong Buy” on Edwards Lifesciences Corporation, with a fair value of $85 per share, due to strategic focus on structural heart and new product investments. Edwards Lifesciences reported 9.6% organic revenue growth and a 7.2% increase in the Transcatheter Aortic Valve Replacement segment in Q3 2024. The sale of the Critical Care business for $4.2 billion will fund share buybacks, acquisitions, and strategic investments, enhancing growth in high-potential areas.
Investors Are Invited To Join The Schall Law Firm In A Securities Fraud Case Against Edwards Lifesciences Corporation
LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024.
EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.
